Search

Your search keyword '"Nandakumar, Subhiksha"' showing total 303 results

Search Constraints

Start Over You searched for: Author "Nandakumar, Subhiksha" Remove constraint Author: "Nandakumar, Subhiksha"
303 results on '"Nandakumar, Subhiksha"'

Search Results

1. Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors

3. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

4. Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.

5. Tracking the FDA precision oncology drug approval landscape in OncoKB.

6. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer

7. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

8. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

9. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

10. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

12. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

13. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response

14. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages

15. Figure S1 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

16. Table S3 from Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

17. Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

18. Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

19. Supplementary Figure S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

20. Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

21. MODL-37. MODELING REVERSIBLE TUMORIGENESIS IN CEREBRAL ORGANOIDS

22. PATH-27. DROPLET DIGITAL PCR ENHANCES DETECTION OF HOTSPOT MUTATIONS IN CIRCULATING TUMOR DNA FROM CEREBROSPINAL FLUID OF PATIENTS WITH HIGH-GRADE GLIOMA

23. PR046/#280 The genomic landscape of distant metastatic endometrial cancer

24. NIMG-38. TUMOR VOLUME GROWTH RATES AND DOUBLING TIMES DURING ACTIVE SURVEILLANCE OF IDH-MUTANT LOW-GRADE GLIOMA

25. Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.

26. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

27. Supplementary Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

28. Supplementary Figure from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort

29. Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

30. Supplementary Data from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort

31. Data from Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort

32. Abstract 1053: Circulating tumor DNA from cerebrospinal fluid (CSF) allows for characterization and monitoring of glioma patients

33. Supplemental Table 2 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

34. Supplementary Appendix from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

35. Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

36. Table S8 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

37. Supplementary Data from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)

38. Supplemental Table 3 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

39. Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression

40. Figure S6 from A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)

41. Figure S2 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

42. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

43. Supplementary Tables 1-6 and Supplementary Figures 1-6 from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer

44. Supplementary Data from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer

45. Supplemental Table 1 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

46. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

47. Supplemental Figure 1 from Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

48. The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer

50. IncreasedMYBL2expression in aggressive hormone‐sensitive prostate cancer

Catalog

Books, media, physical & digital resources